Director Josef Parvizi of Ceribell, Inc. completed a sale of 16,714 shares of common stock on February 19, 2026, generating proceeds of $338,792. The transaction recorded an average price of $20.27 per share, with individual lots executed at prices spanning $20.00 to $20.77.
The sale was carried out pursuant to a pre-established trading arrangement under Rule 10b5-1 that Parvizi adopted on August 18, 2025. After the disposition, Parvizi retains significant indirect holdings across three trusts: 722,652 shares through the Josef Parvizi Trust, 907,911 shares through the Innovation ACP Trust, and 369,088 shares through the ACP 2021 Trust.
Market context noted alongside the filing indicates Ceribell's shares have climbed 68% over the preceding six months. InvestingPro analysis cited in filings suggests the stock is currently trading above its Fair Value.
Recent corporate developments
- Regulatory: The U.S. Food and Drug Administration granted Breakthrough Device Designation for Ceribell's Large Vessel Occlusion (LVO) stroke detection monitor. The device leverages the company’s existing electroencephalography hardware combined with an AI-based algorithm to assist in early detection of LVO strokes in hospital settings.
- Board change: Lucian Iancovici resigned from Ceribell’s board of directors effective December 31, 2025. The company reported no disagreements with Mr. Iancovici regarding corporate operations or policies.
- Analyst coverage: BTIG reiterated a Buy rating on Ceribell and maintained a $30 price target, highlighting the company’s forecasted 30% year-over-year growth for 2026.
- Real estate: Ceribell extended two office leases in Sunnyvale, California, through January 2028. The extended space totals 11,607 square feet, with a monthly rent obligation of $34,821.
Analysis and context
The insider sale was executed within the boundaries of a Rule 10b5-1 program, indicating the transaction followed a pre-determined trading schedule rather than an ad hoc decision. Parvizi maintains material indirect ownership via three trusts, leaving him with substantial exposure to Ceribell equity even after the sale.
The package of regulatory recognition, analyst affirmation, and office-lease extensions illustrates a mix of operational, strategic, and regulatory activities unfolding at the company. The FDA Breakthrough Device designation for the LVO monitor is a notable regulatory milestone for Ceribell’s product set, while the leased space extensions reflect ongoing facilities commitments in Sunnyvale.
Key takeaways
- Insider sale: 16,714 shares sold for $338,792 on February 19, 2026, under a Rule 10b5-1 plan.
- Regulatory progress: FDA granted Breakthrough Device Designation for the LVO stroke detection monitor.
- Operational updates: Board resignation effective December 31, 2025; BTIG reiterates Buy with $30 target and projects 30% YoY growth in 2026; Sunnyvale lease extensions cover 11,607 square feet at $34,821 per month.
Summary
Ceribell reported a director-initiated sale that followed an existing 10b5-1 plan while retaining substantial indirect shareholdings through multiple trusts. The company simultaneously disclosed regulatory progress, an executive-level board change, analyst support, and facility lease extensions. InvestingPro analysis flags the shares as trading above Fair Value despite a 68% six-month rally.